Patents Assigned to MEDSHINE DISCOVERY INC.
  • HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR
    Publication number: 20200039995
    Abstract: 10-oxo-6,1-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine-9-carboxylic acid derivatives of formula (I) as hepatitis B surface antigen inhibitors or pharmaceutically acceptable salts thereof, and uses of a compound of formula (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof in preparation of medicaments for treatment of viral hepatitis B.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 6, 2020
    Applicants: FUJIAN COSUNTER PHARMACEUTICAL CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Fei SUN, Jinhua DU, Yanbin HU, Lili ZHOU, Charles Z. DING, Shuhhui CHEN
  • Benzotriazole-derived ? and ?-unsaturated amide compound used as TGF-? RI inhibitor
    Patent number: 10548883
    Abstract: A benzotriazole-derived ? and ?-unsaturated amide compound used as TGF-?R1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I).
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: February 4, 2020
    Assignees: Genfleet Therapeutics (Shanghai) Inc., Medshine Discovery Inc.
    Inventors: Fei Sun, Lifang Wu, Charles Z. Ding, Guoping Hu, Jian Li, Shuhui Chen, Jianyu Lu
  • Cyclic compound acting as PDE4 inhibitor
    Patent number: 10532986
    Abstract: Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 14, 2020
    Assignee: Medshine Discovery Inc.
    Inventors: Yunfu Luo, Chundao Yang, Maoyi Lei, Lanbao Sun, Guoping Hu, Jian Li, Shuhui Chen
  • NOVEL BETA-LACTAMASE INHIBITORS
    Publication number: 20200010467
    Abstract: Disclosed in the present invention is a type of novel ?-lactamase inhibitors, and specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 2, 2017
    Publication date: January 9, 2020
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Boyu HU, Charles Z. DING, Zhigang HUANG, Ruibin LIN, Minliang XIAO, Jinsheng XIE, Shuhui CHEN, Cheng LI
  • Vinyl compounds as FGFR and VEGFR inhibitors
    Patent number: 10519133
    Abstract: FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: December 31, 2019
    Assignees: MEDSHINE DISCOVERY INC., HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Shuhui Chen, Zhengxia Chen, Meibi Dai, Cheng Xie, Peng Li, Yang Zhang, Guibai Liang, Qiang Wang, Jiangpeng Liao, Fei Sun, Guoping Hu, Jian Li
  • Benzimidazole-linked indole compound acting as novel divalent IAP antagonist
    Patent number: 10508103
    Abstract: The present invention discloses a benzimidazole-linked indole compound acting as novel divalent IAP antagonist, specifically disclosing the compound shown in formulas (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: December 17, 2019
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Fei Sun, Charles Z. Ding, Zhe Cai, Wenyuan Qian, Guoping Hu, Jian Li, Shuhui Chen
  • Tricyclic compound serving as immunomodulator
    Patent number: 10487088
    Abstract: Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: November 26, 2019
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Medshine Discovery Inc.
    Inventors: Shilan Liu, Dahai Wang, Guibai Liang, Guoping Hu, Jian Li, Shuhui Chen
  • CRYSTAL AND SALT OF NITROIMIDAZOLE, AND MANUFACTURING METHOD THEREOF
    Publication number: 20190276475
    Abstract: The present invention discloses a crystal form and salt of a nitroimidazole compound, and a manufacturing method thereof. The invention further comprises an application of the crystal form and salt in preparing a pharmaceutical product for preventing and treating an infection caused by Mycobacterium tuberculosis or another microbe.
    Type: Application
    Filed: July 21, 2017
    Publication date: September 12, 2019
    Applicant: Medshine Discovery Inc.
    Inventors: Wei LUO, Charles Z. DING, Zhigang HUANG, Yinghu HU, Zongbin LI, Qingqing LU
  • Linkers and their application towards ADC
    Patent number: 10280229
    Abstract: The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: May 7, 2019
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Chun Sing Li, Jian Li, Yong Cang, Shuhui Chen, Gang Li, Xiongbin Xu, Lun Lu
  • Anti-pulmonary tuberculosis nitroimidazole derivative
    Patent number: 10227362
    Abstract: Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: March 12, 2019
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wei Luo, Charles Z. Ding, Zhigang Huang, Shuhui Chen
  • Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof
    Patent number: 10183915
    Abstract: Disclosed are two axially chiral isomers and pharmaceutically available salts thereof, preparation method therefor, and pharmaceutical use of the two axially chiral isomers or pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: January 22, 2019
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Jianfei Wang, Jing Zhang, Long Zhang, Yang Zhang, Jian Li, Shuhui Chen
  • ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE
    Publication number: 20180162878
    Abstract: Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.
    Type: Application
    Filed: January 28, 2016
    Publication date: June 14, 2018
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Wei LUO, Charles Z. DING, Zhigang HUANG, Shuhui CHEN
  • TOLL-LIKE RECEPTOR-7 AGONIST
    Publication number: 20180148452
    Abstract: Disclosed are a novel pyrrolopyrimidine ring compound as a TLR7 agonist or a pharmaceutically acceptable salt thereof, used for preventing or treating allergic rhinitis and asthma. In particular, disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 29, 2015
    Publication date: May 31, 2018
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Charles Z. DING, Fei SUN, Lifang WU, Jinhua DU, Yasuhiro KATSU, Guoping HU, Jian LI
  • Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
    Patent number: 9969719
    Abstract: Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 15, 2018
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Charles Z. Ding, Shuhui Chen, Baoping Zhao, Zhaobing Xu, Yingchun Liu, Ruibin Lin, Fei Wang, Jian Li
  • Isoquinolinesulfonyl derivative as RHO kinase inhibitor
    Patent number: 9856264
    Abstract: The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 2, 2018
    Assignee: Medshine Discovery Inc.
    Inventors: Lingyun Wu, Yuanshan Yao, Zhaoguo Chen, Shuhui Chen
  • Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors
    Patent number: 9856262
    Abstract: Disclosed is a series of analogs of 4H-pyrazolo[1,5-?]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: January 2, 2018
    Assignees: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., Humanwell Healthcare (Group) Co., Ltd., Medshine Discovery Inc.
    Inventors: Xuehai Wang, Zhaozhong Ding, Yong Xu, Shuhui Chen, Lie Li, Gang Li, Ronghua Tu, Cailin Wang, Yang Yue, Zhibo Zhang, Hailiang Chen, Wenjie Sun, Lu Huang
  • HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF
    Publication number: 20170326149
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Application
    Filed: September 22, 2015
    Publication date: November 16, 2017
    Applicants: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, MEDSHINE DISCOVERY INC.
    Inventors: Lingyun WU, Chaofeng LONG, Peng ZHANG, Xiaoxin CHEN, Li ZHANG, Zhuowei LIU, Jian LI, Shuhui CHEN
  • DGAT1 inhibitor and preparation method and use thereof
    Patent number: 9809604
    Abstract: The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: November 7, 2017
    Assignees: Qingdao Huanghai Pharmaceutical Co., Ltd., Medshine Discovery Inc.
    Inventors: Chengde Wu, Zhiliu Zhang, Tao Yu
  • LINKERS AND THEIR APPLICATION TOWARDS ADC
    Publication number: 20170202974
    Abstract: The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.
    Type: Application
    Filed: July 13, 2015
    Publication date: July 20, 2017
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Chun Sing LI, Jian LI, Yong CANG, Shuhui CHEN, Gang LI, Xiongbin XU, Lun LU
  • DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR
    Publication number: 20170197986
    Abstract: Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2015
    Publication date: July 13, 2017
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Haiying HE, Kai ZHOU, Hua QIN, Xiaolin LI, Yuedong ZHOU, Xiaofei WANG, Xuemei CHI, Jian LI, Shuhui CHEN